Brief: SinoMab Bioscience Says Biologics License Application Accepted By NMPA For SM03 (Suciraslimab)
05/09/2023 08:43
Sept 5 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* BIOLOGICS LICENSE APPLICATION ACCEPTED BY NMPA FOR SM03
(SUCIRASLIMAB) IN TREATMENT OF RHEUMATOID ARTHRITIS
Source text for Eikon: ID:nHKS9C5BMW
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience